PALI

+ Watchlist + Portfolio

Palisade Bio, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.43
52-Week Range: $1.32 – $2.86
Market Cap: $250.95M
P/E (TTM): 2.40
EPS (TTM): 0.60
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.05
PEG Ratio: —
Return on Equity: -51.37%
Return on Assets: -32.98%
Gross Margin: 100.00%
Operating Margin: -2339.60%
Profit Margin: 0.00%
Current Ratio: 24.26
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-8.65M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $125.78M

PALI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$250.00K	$0.00	$0.00
Research & Development	$6.55M	$6.89M	$9.06M	$10.19M
Selling, General & Admin	$8.76M	$6.20M	$5.80M	$7.86M
Operating Expenses	$15.31M	$13.10M	$14.86M	$18.06M
Operating Income	-$15.31M	-$12.85M	-$14.86M	-$18.06M
EBITDA	-$14.24M	-$12.28M	-$14.42M	-$16.77M
Pretax Income	-$14.26M	-$12.30M	-$14.44M	-$16.78M
Net Income	-$14.26M	-$12.30M	-$14.44M	-$16.78M
Diluted EPS	-247.95	-27.01	-10.19	-0.30
Diluted Shares	58687	456014	1.42M	55.67M

PALI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$12.38M	$12.43M	$9.82M	$133.38M
Receivables	$1.44M	$148.00K	$24.00K	$264.00K
Current Assets	$14.73M	$13.33M	$10.49M	$134.22M
Total Assets	$15.76M	$14.05M	$10.88M	$134.34M
Current Liabilities	$3.01M	$2.59M	$3.24M	$4.64M
Total Debt	$404.00K	$369.00K	$169.00K	$71.00K
Total Liabilities	$3.28M	$2.74M	$3.39M	$4.96M
Retained Earnings	-$109.19M	-$121.51M	-$135.94M	-$152.72M
Shareholders' Equity	$12.48M	$11.31M	$7.49M	$129.38M
Working Capital	$11.72M	$10.74M	$7.26M	$129.59M

PALI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$13.36M	-$11.13M	-$12.19M	-$10.85M
Capital Expenditure	-$10.00K	-$4.00K	—	—
Free Cash Flow	-$13.37M	-$11.14M	-$12.19M	-$10.85M
Depreciation & Amortisation	$3.00K	$4.00K	$3.00K	$3.00K
Stock-Based Compensation	$1.03M	$624.00K	$652.00K	$3.96M
Investing Cash Flow	-$10.00K	-$4.00K	$0.00	—
Financing Cash Flow	$15.26M	$11.19M	$9.58M	$134.44M
Net Change in Cash	$1.89M	$49.00K	-$2.61M	$123.59M

PALI Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$500.00K
Research & Development	$950.00K	$1.68M	$1.39M	$6.17M	$6.40M	$7.40M
Selling, General & Admin	$1.36M	$1.17M	$1.53M	$3.81M	$4.35M	$4.80M
Operating Expenses	$2.31M	$2.84M	$2.92M	$9.98M	$10.75M	$12.20M
Operating Income	-$2.31M	-$2.84M	-$2.92M	-$9.98M	-$10.75M	-$11.70M
EBITDA	-$2.23M	-$2.78M	-$2.86M	-$8.90M	-$9.60M	-$10.57M
Pretax Income	-$2.23M	-$2.78M	-$2.87M	-$8.90M	-$9.60M	-$10.57M
Net Income	-$2.23M	-$2.78M	-$2.87M	-$8.90M	-$9.60M	-$10.57M
Diluted EPS	-0.47	-0.58	-0.38	—	-0.05	-0.05
Diluted Shares	4.80M	4.80M	7.47M	—	209.66M	211.38M

PALI Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$7.23M	$5.42M	$5.23M	$133.38M	$132.63M	$125.17M
Receivables	$78.00K	$6.00K	$18.00K	$264.00K	$9.00K	$503.00K
Current Assets	$7.89M	$6.45M	$6.83M	$134.22M	$133.24M	$127.26M
Total Assets	$8.19M	$6.67M	$6.97M	$134.34M	$133.31M	$127.31M
Current Liabilities	$2.78M	$3.97M	$3.48M	$4.64M	$5.62M	$5.25M
Total Debt	$58.00K	$338.00K	$211.00K	$71.00K	—	—
Total Liabilities	$2.86M	$4.05M	$3.76M	$4.96M	$5.95M	$5.57M
Retained Earnings	-$138.17M	-$140.96M	-$143.83M	-$152.72M	-$162.32M	-$172.90M
Shareholders' Equity	$5.33M	$2.62M	$3.21M	$129.38M	$127.36M	$121.75M
Working Capital	$5.11M	$2.48M	$3.35M	$129.59M	$127.62M	$122.01M

PALI Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$2.33M	-$1.82M	-$3.55M	-$3.14M	-$3.89M	-$7.60M
Free Cash Flow	-$2.33M	-$1.82M	-$3.55M	-$3.14M	-$3.89M	-$7.60M
Depreciation & Amortisation	$1.00K	$1.00K	$1.00K	$0.00	$0.00	$0.00
Stock-Based Compensation	$69.00K	$69.00K	$90.00K	$3.73M	$4.30M	$4.79M
Financing Cash Flow	-$258.00K	$4.00K	$3.36M	$131.33M	$3.13M	$147.00K
Net Change in Cash	-$2.59M	-$1.81M	-$190.00K	$128.19M	-$757.00K	-$7.46M

Market Snapshot

About

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing therapies for gastrointestinal inflammation and diseases. The company targets acute and chronic conditions affecting the digestive system, aiming to address unmet medical needs in GI health with novel treatment approaches.